Ultime notizie per Peak Bio (OTC:PKBO) Azioni

Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology, inflammation and rare diseases.

Peak Bio Inc

NPABU

Trading Halt: Halted at 4:04:29 p.m. ET - Trading Halt: Halt News Pending

NPAB

NPABW

U.S. federal authorities have disclosed an assassination plot by Iranian operatives, targeting <a href="https://www.benzinga.com/topic/donald-trump">former President Donald Trump. </a>
The plan, unveiled on Friday, involved recruiting criminal assets to monitor and ultimately kill him on American soil, the AP News <a href="https://apnews.com/article/iran-fbi-justice-department-iran-83cff84a7d65901a058ad6f41a564bdb">reports</a>.
What Happened: The Justice Department released details of the plot following the indictment of Farhad Shakeri, an alleged Iranian government operative. Shakeri reportedly received orders from Iran&#8217;s Revolutionary Guard to organize surveillance on Trump and prepare for a possible assassination attempt, per federal court filings. 
The instructions reportedly came with an urgent seven-day deadline. Authorities stated that Shakeri's handlers implied the operation would be easier if Trump lost the election, expecting a potential delay if he remained in office, the AP reports. 
Shakeri remains at large in Iran, while two other suspects linked to separate Iranian-backed assassination schemes have been apprehended. 
Also Read: <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">Trump Says He Won&#8217;t Sell Trump Media Stock</a>
According to the Department of Justice, Tehran's attempts to disrupt the U.S. political landscape have included both physical threats and cyber operations. A previous incident involved Iranian hackers attempting to distribute stolen Trump campaign data to Joe Biden's team. Intelligence sources confirmed that no response came from Biden's camp <a href="https://www.benzinga.com/news/24/09/40933501/us-intel-agencies-reveal-iran-tried-to-share-hacked-trump-campaign-data-with-team-biden-fbi-says-no">regarding these phishing attempts.</a>
Why It Matters: This assassination plot is part of a broader Iranian strategy to challenge and destabilize American security. Following the high-profile killing of Gen. Qassem Soleimani under Trump's orders, Iranian leaders pledged retribution, intensifying hostile operations against U.S. figures, according to the AP.
Attorney General Merrick Garland, addressing these developments, reiterated that Iran's provocative actions remain a grave concern for U.S. national security. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a></li>
</ul>
Photo: Shutterstock

Politics

Global

Iranian Plot Against Trump Unveiled As Tensions With US Grow

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.19) by 68.91 percent.

Earnings

Earnings Beats

News

APTO

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

This year's MJBizCon in Las Vegas promises to deliver crucial insights from industry pioneers, with two key panels featuring <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis'</a> managing director <a href="https://www.benzinga.com/author/javier-hasse">Javier Hasse</a>, along with renowned voices in the cannabis sector. These sessions will provide actionable knowledge for entrepreneurs and investors navigating the burgeoning cannabis industry, including pivotal discussions on brand building and the rapid evolution of Latin American cannabis markets.
<h3 class="wp-block-heading">Embracing Your Brand's Unique Magic: How To Build An Iconic Brand In The Ancillary Market</h3>
Date &amp; Time: Wednesday, December 4, 2024, 2:00pm – 2:40pm Location: Room 2 &#8211; Cannabis Business 101
In this session, cannabis branding is the focal point, led by <a href="https://www.benzinga.com/markets/cannabis/24/08/40140453/how-a-simple-magic-trick-led-to-one-of-the-most-recognized-cannabis-related-brands-in-the-world-">Josh Kesselman</a>, CEO and founder of <a href="https://www.benzinga.com/markets/cannabis/24/07/40076950/raw-rolling-papers-are-not-drug-paraphernalia-court-confirms">RAW Rolling Papers</a>, a globally recognized brand rooted in authenticity and simplicity. Known for his unfiltered approach, Kesselman's journey—from opening a smoke shop to founding a major brand—demonstrates the power of authenticity in establishing a loyal customer base.
For those exploring opportunities in the cannabis ancillary market, Kesselman's insights will be invaluable. As he explains, the ancillary market remains a fertile ground for entrepreneurs free from stringent regulations that often accompany cannabis itself. Topics include unconventional marketing approaches and how to leverage technology and security to amplify brand presence. 
Javier Hasse's expertise in content and cannabis market growth adds an additional layer, with his experience shaping media narratives for both Benzinga and <a href="https://elplanteo.com/">El Planteo</a>. This panel invites entrepreneurs to think innovatively in a field where standing out is essential.
<h3 class="wp-block-heading">Cannabis In Latin America: Market Evolution And Opportunities</h3>
Date &amp; Time: Friday, December 6, 2024, 10:00am – 10:40am Location: Room N110 &#8211; International Regulatory Roundup
As cannabis markets continue to expand in Latin America, this panel explores the region's distinct landscape. Javier Hasse will join a discussion with industry leaders, including <a href="https://www.benzinga.com/markets/cannabis/24/06/39114436/how-3-chilean-brothers-built-a-global-cannabis-platform-embraced-by-big-sponsors-like-adidas-and">Simón Espinosa</a>, CEO of En Volá; Julian Wilches, co-founder and CRO at Clever Leaves (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLEVER#OTC">CLEVER</a>); and Zara Snapp, director at Instituto RIA. Together, they will dissect the evolving regulatory frameworks, investment potential and unique challenges in key countries such as Argentina, Mexico, Chile and Colombia.
This conversation will provide critical insights into how regulatory and social dynamics shape opportunities in Latin America, a region gaining prominence as both a cultivator and consumer of cannabis. Espinosa's experience with En Volá offers a cultural perspective, while Wilches and Snapp bring expertise in regulatory compliance and policy reform. Attendees will walk away with a nuanced understanding of how to navigate these diverse markets, the importance of local partnerships, and strategies for sustainable growth amid complex regulations.
More details <a href="https://mjbizconference.com/">here</a>.

Cannabis

Legal

Events

CLEVER

Josh Kesselman, Javier Hasse And More Experts Dive Into Cannabis Market Trends At MJBizCon

Donald Trump's 2024 presidential election win is already having an impact on<a href="https://www.benzinga.com/general/politics/24/11/41817245/will-trump-be-sentenced-in-hush-money-trial-or-will-his-criminal-problems-go-away"> his pending court cases</a>: a federal judge paused a 2020 election interference prosecution from Special Counsel Jack Smith Friday.
What Happened: Trump's defeat of Vice President Kamala Harris in <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">the 2024 presidential election</a> will put him back in the White House in January 2025. The election win could make it possible for Trump to avoid courtrooms in the future, with pending cases likely to be dismissed and thrown out.
On Friday, U.S. District Judge Tanya Chutkan paused a case against Trump related to election interference claims. Special Counsel Jack Smith previously charged Trump with trying to remain in the White House after the 2020 election despite losing to President Joe Biden.
Smith filed to pause the proceedings and said he plans to make a filing on Dec. 2 about how the criminal case should proceed now that Trump will be president again, as reported by <a href="https://www.bloomberg.com/news/articles/2024-11-08/us-special-counsel-asks-court-to-pause-trump-prosecution?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>.
Justice Department policy prevents the current president from being prosecuted, according to the report. Smith said the case will likely be dropped due to this policy.
On Friday, Smith said in a filing that he needs "time to assess this unprecedented circumstance and determine the appropriate course going forward" due to the Department of Justice policy.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: The 2020 election interference isn't the only case impacted by Trump's 2024 win.
Trump was previously found guilty on 34 counts of falsifying business records in what is known as the hush money trial. Sentencing in the case was delayed several times by Judge Juan Merchan and a sentencing date of Nov. 26 is now in question after Trump's election victory.
As <a href="https://www.benzinga.com/general/politics/24/11/41817245/will-trump-be-sentenced-in-hush-money-trial-or-will-his-criminal-problems-go-away">Benzinga reported Thursday</a>, legal experts are skeptical that Merchan would still carry out sentencing of the future sitting president. Merchan also plans to issue a ruling by Nov. 12 on Trump's legal team's request to toss out the guilty verdict after the Supreme Court issued partial immunity to former presidents earlier this year.
Trump faces potential punishment of up to four years in prison for each guilty verdict, with a limit of 20 total years in prison. While prison time is unlikely due to his lack of a previous criminal record, Trump could receive probation or home confinement.
If Merchan chooses to continue with sentencing he would be tasked with deciding whether to defer the sentencing to 2029 when Trump is out of the White House, delay Trump's punishment until 2029 or try to place the punishment on Trump while he's in office.
A classified documents case against Trump saw the former president charged in June 2023. The case, which was also brought against Trump by Smith, is also expected to be dismissed after the election result, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-08/can-trump-go-to-jail-after-2024-election-win-whats-next-in-his-criminal-cases?itm_source=record&amp;itm_campaign=Trump_Legal_Troubles&amp;itm_content=What%27s_Next-1&amp;sref=TBDibEcD">reported</a>.
A case against Trump in the state of Georgia saw charges brought against the former president in August 2023 related to conspiracy in the 2020 election. Trump's legal team is preparing for an argument to dismiss the case due to his return to the White House.
Among the reasons legal experts expect the cases to be dropped against Trump is a fear of retaliation against the judges and lawyers involved in cases.
On Thursday, Trump ally Mike Davis issued a warning to New York Attorney General Letitia James during an appearance on "The Benny Show" podcast.
"I dare you to try to continue your lawfare against President Trump in his second term," Davis said, as <a href="https://nypost.com/2024/11/07/us-news/trump-ally-mike-davis-warns-ny-ag-letitia-james-to-back-off-president-elect/">reported </a>by the New York Post. "Listen her, sweetheart, we're not messing around this time and we will put your fat a&#8211; in prison for conspiracy against rights. I promise you that."
James won a $454 million civil fraud judgment in the state of New York related to Trump and the Trump Organization's business dealings in the state. On Wednesday, James said she would "use the rule of law to fight back" against Trump. The president-elect has appealed the ruling in New York.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">Donald Trump&#8217;s Wealth Soars With 2024 Election Win: Here&#8217;s How Much President-Elect Is Worth, How Much He&#8217;ll Make In White House</a></li>
</ul>
Photo via Shutterstock.

Trump 2020 Election Interference Case Paused: How 2024 Election Win Is Impacting President-Elect's Legal Troubles

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher Friday after climbing new highs during the week. Here&#8217;s what <a href="https://www.benzinga.com/quote/PLTR/news">you need to know.</a>
The Details: On Monday, Palantir <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">reported third-quarter revenue</a> of $725.52 million, surpassing the $701.13 million estimate and earnings per share of 6 cents, beating expectations of 4 cents. Total revenue rose 30% year-over-year, with U.S. commercial revenue up 54% and U.S. government revenue up 40%. CEO Alex Karp added that the company's growth is "driven by unrelenting AI demand that won't slow down."
Shares<a href="https://www.benzinga.com/news/earnings/24/11/41746288/palantir-stock-is-hitting-new-highs-whats-going-on"> continued to rise </a>after some analysts commented on Palantir's expanding U.S. customer base and AI product demand. Analysts at Wedbush, Mizuho and DA Davidson all raised their price targets, with Wedbush's Dan Ives citing Palantir's "robust" results and AI expansion. 
The stock hit another all-time high on <a href="https://www.benzinga.com/news/earnings/24/11/41782430/palantir-shares-are-hitting-new-highs-on-wednesday-whats-going-on">Wednesday </a>after Donald Trump's presidential win sparked market optimism on potential policy shifts, which could favor defense and AI sectors. Palantir, up 25% over the past week, was seen as a potential beneficiary of a Trump administration&#8217;s defense and intelligence priorities.
Palantir shares also <a href="https://www.benzinga.com/news/24/11/41808861/whats-going-on-with-palantir-stock-thursday">faced early pressure</a> after Jefferies downgraded the stock from Hold to Underperform, citing valuation concerns. However, the stock bounced back intraday Thursday after Palantir announced a partnership with Amazon Web Services (AWS) and Anthropic to bring advanced AI capabilities to U.S. defense and intelligence agencies. The partnership will integrate Anthropic&#8217;s Claude AI models into Palantir's AI Platform for secure government use.
PLTR Price Action: Palantir shares were up 4.60% at $58.44 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-1024x542.png" alt="" class="wp-image-638322" style="width:469px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08133801/PLTR.png 1180w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41853996/sony-posts-upbeat-earnings-joins-tesla-upstart-doximity-fortrea-axon-enterprise-and-other-big-stocks-moving-higher-on-friday">Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday</a></li>
</ul>
Image Via Shutterstock.

Movers

PLTR

What's Going On With Palantir Stock This Week?

Throughout the last three months, 4 analysts have evaluated Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dianthus Therapeutics, revealing an average target of $46.0, a high estimate of $56.00, and a low estimate of $40.00. Marking an increase of 5.34%, the current average surpasses the previous average price target of $43.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1731099673_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Dianthus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dianthus Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dianthus Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dianthus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dianthus Therapeutics</h2>
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
<h3>Understanding the Numbers: Dianthus Therapeutics's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dianthus Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 92.26%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -945.09%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Dianthus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dianthus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Dianthus Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

DNTH

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is reportedly considering the sale of Jeppesen, a navigation unit it acquired in 2000, to reduce its $58 billion debt. <a href="https://www.bloomberg.com/news/articles/2024-11-08/boeing-is-exploring-possible-6-billion-sale-for-jeppesen-unit?srnd=homepage-americas">Bloomberg reported </a>that the company is working with an adviser on a sale that could bring in more than $6 billion. 
The unit, which provides navigation tools to airlines, has already attracted interest from many private equity firms.
The possible divestment follows CEO Kelly Ortberg's review of Boeing's assets to identify units that may no longer align with the company&#8217;s focus on core commercial aircraft production. Ortberg said in an earnings call that he's looking at "whether a business or product fits with the long-term strategy or whether it would be better off someplace else."
Ortberg also confirmed that Boeing will pay employees furloughed during the seven-week strike in Seattle, according to a <a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.">BNN Bloomberg report.</a> "We want to acknowledge your support by returning your lost pay," the CEO said in an internal memo. 
However, the company plans more job cuts to reduce costs. Boeing has already been cutting costs with hiring freezes and corporate travel reductions to handle its cash shortage.
BA Price Action: Boeing shares were up 0.48% at $151.70 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png" alt="" class="wp-image-638240" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08125901/BA-1.png 1185w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41853052/how-much-is-nintendo-suing-palworld-for-patents-financial-details-unveiled">How Much Is Nintendo Suing Palworld For? Patents, Financial Details Unveiled</a></li>
</ul>
Image Via Shutterstock.

What's Going On With Boeing Shares Today?

TVGN

Tevogen Bio Nears Finalization Of R&D And Manufacturing Expansion Deal With CD8 Technology; Secures $36M Line Of Credit To Support Operations And Long-Term Growth

Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) shares are trading higher Friday. The company revealed plans to hire over 1,000 employees to support the sales push for its new AI product, Agentforce, which targets the growing demand for AI-driven automation across various business functions. Here&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41607435/salesforce-launches-agentforce-redefining-ai-in-business-with-autonomous-solutions">what you need to know.</a>
What To Know: <a href="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push">According to Bloomberg</a>, Agentforce is designed to help companies set up AI agents capable of performing tasks like customer service, marketing and order management autonomously. The product integrates with Salesforce&#8217;s Customer 360 platform, making it part of the company's broader shift toward AI-powered business automation. Initial pricing for Agentforce is about $2 per agent conversation and Salesforce reports positive initial customer feedback.
CEO Marc Benioff described the hiring expansion as a response to "amazing momentum" for the generative AI tool, noting positive customer feedback since its launch two weeks ago.
In addition to these new hires, Salesforce's stock may have also gained momentum due to a "Golden Cross" technical signal, which indicates that its short-term (50-day) moving average has moved above its long-term (200-day) moving average.
Benioff commented on the move, highlighting the "incredible momentum" behind Agentforce and expressing confidence in the company's ability to capture new growth opportunities in AI. 
CRM Price Action: Salesforce shares were up 3.59% at $321.94 at the time of writing, according to Benzinga Pro.
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08151403/CRM-1024x547.png" alt="" class="wp-image-638463" style="width:420px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08151403/CRM-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08151403/CRM-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08151403/CRM-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08151403/CRM.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41856124/why-natures-miracle-nmhi-stock-is-down-28">Why Nature&#8217;s Miracle (NMHI) Stock Is Down 28%</a></li>
</ul>
Image Via Shutterstock.

Salesforce Shares Are Trading Higher Today: What You Need To Know

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-08_08h12_07.png" alt="" style="width:624px" /></figure>
<h4 class="wp-block-heading">Nvidia As An Indicator</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-trump-hopium-nvidia-indicator-china-stimulus-nvda-mc-11082024">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA stock is being used to illustrate the point.</li>
<li>The chart shows that NVDA has broken out.</li>
<li>RSI on the chart shows that NVDA has room to run.</li>
<li>Nvidia will report earnings on Nov. 20 after the market close.&nbsp; Historically, NVDA stocks sees heavy buying before earnings. As full disclosure, in addition to the core position in NVDA, which is long from $12.55, The Arora Report also has a trade around position in NVDA in The Arora Report&#8217;s ZYX Buy.</li>
<li>The chart shows the top support zone.&nbsp; This top support zone is very significant as an indicator for the entire market, not just NVDA stock.</li>
<li>For the time being, as a simple short cut, investors can use Nvidia as an indicator.&nbsp; As long as NVDA stock does not break below the top support zone, investors' stance towards the stock market should be bullish.&nbsp; The short cut is helpful but consider relying on the highly sophisticated, adaptive, <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model </a>with inputs in 10 categories.</li>
<li>The Arora Report call is to scale in by buying stocks and ETF's, not just NVDA, as they dip in the buy zones until a time when Trump hopium comes close to meeting reality.</li>
<li>In The Arora Report analysis, the time to take profits will be just before the Trump hopium comes close to meeting reality.&nbsp;&nbsp;</li>
<li>The stock market is moving based on the difference between Wall Street positioning going into the election and the election result.&nbsp; In The Arora Report analysis, the main cause of the rip roaring rally after the election is two-fold:
<ul>
<li>Wall Street was not positioned for the margin of Trump's victory.</li>
<li>Wall Street was not positioned for a potential red sweep.&nbsp; As of this writing, there is a high probability of a red sweep, but it is not yet confirmed.&nbsp; A red sweep will take place if Republicans take control of the House.</li>
</ul>
</li>
<li>Based on anecdotal evidence, it is difficult for many investors to put their arms around the current rally and The Arora Report's call to buy the dips.&nbsp; </li>
<li>In the early trade, the Trump rally is taking a breather for two reasons:
<ul>
<li>Investors' disappointment from China stimulus first impacted Asian markets, then moved to Europe, and now to the U.S.&nbsp; See the section below for details.</li>
<li>In the very very short term, the stock market is overbought.</li>
</ul>
</li>
<li>The University of Michigan Consumer Sentiment &#8211; Prelim will be released at 10am ET.&nbsp; It may be market moving.</li>
<li>In The Arora Report analysis, consumer sentiment has moved up significantly after Trump's election.&nbsp;&nbsp;&nbsp;</li>
</ul>
<h4 class="wp-block-heading">Big China Stimulus</h4>
China has announced a big stimulus of $1.4T.&nbsp; The stimulus will provide swaps for debt ridden local governments' off balance sheet liabilities.&nbsp; The size of the stimulus is greater than the consensus.&nbsp; For this reason, it should have been positive, but in The Arora Report analysis, investors are reacting negatively because the stimulus did not include any fiscal measures to boost the economy.&nbsp;&nbsp;
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are neutral in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVDA.
In the early trade, money flows are negative in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is being bought on hope that whales will take advantage of low liquidity during the weekend to run bitcoin up over $80,000.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  The proprietary protection band from The Arora Report is very popular.  The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Markets

ETFs

General

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Scale In On Trump Hopium Dips – Watch Nvidia As An Indicator, Big China Stimulus

GRFS

Mason Capital Criticizes Grifols Board For Governance Failures And Shareholder Value Loss; Calls For Independent Directors And Improved Oversight; Claims Brookfield Transaction Undervalues Grifols

AUTL

FDA Approves Obecabtagene Autoleucel (Aucatzyl) For Adults With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; 42% Achieved Complete Remission Within 3 Months

Asset Sales

Reuters Reported Boeing Close To Funding Agreement To Help Supplier Spirit Aerosystems That Could Be Announced In Next Few Days; Spirit Weighing Sale Of Defense Composites Supplier FMI

High-rolling investors have positioned themselves bullish on Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in OKLO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 30 options trades for Oklo. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 36% bearish. Among all the options we identified, there was one put, amounting to $112,500, and 29 calls, totaling $2,339,238.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $2.5 to $40.0 for Oklo over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $2.5 to $40.0 over the preceding 30 days.
<h3>Oklo Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731098929_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$5.2</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$25.00</td>
<td>$510.0K</td>
<td>3.1K</td>
<td>1.2K</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.5</td>
<td>$7.1</td>
<td>$7.5</td>
<td>$26.00</td>
<td>$374.2K</td>
<td>47</td>
<td>520</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.3</td>
<td>$3.45</td>
<td>$40.00</td>
<td>$176.6K</td>
<td>1.1K</td>
<td>610</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$2.4</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$24.00</td>
<td>$112.5K</td>
<td>49</td>
<td>506</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$6.2</td>
<td>$5.1</td>
<td>$5.4</td>
<td>$21.00</td>
<td>$94.5K</td>
<td>940</td>
<td>177</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
<h3>Current Position of Oklo</h3>
<ul>
<li>Trading volume stands at 18,810,980, with OKLO's price down by -1.51%, positioned at $26.16.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Oklo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

OKLO

Check Out What Whales Are Doing With OKLO

Financial giants have made a conspicuous bearish move on Super Micro Computer. Our analysis of options history for Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) revealed 39 unusual trades.
Delving into the details, we found 43% of traders were bullish, while 51% showed bearish tendencies. Out of all the trades we spotted, 23 were puts, with a value of $1,781,693, and 16 were calls, valued at $804,721.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $13.0 and $87.0 for Super Micro Computer, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Super Micro Computer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Super Micro Computer's significant trades, within a strike price range of $13.0 to $87.0, over the past month.
<h3>Super Micro Computer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731098924_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$12.3</td>
<td>$12.25</td>
<td>$12.27</td>
<td>$33.00</td>
<td>$576.5K</td>
<td>2.1K</td>
<td>753</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.55</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$38.00</td>
<td>$135.0K</td>
<td>5.0K</td>
<td>115</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.65</td>
<td>$6.6</td>
<td>$6.65</td>
<td>$24.00</td>
<td>$129.0K</td>
<td>100</td>
<td>350</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$0.58</td>
<td>$0.54</td>
<td>$0.61</td>
<td>$25.00</td>
<td>$88.8K</td>
<td>9.9K</td>
<td>6.2K</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$17.85</td>
<td>$17.7</td>
<td>$17.7</td>
<td>$13.00</td>
<td>$88.5K</td>
<td>512</td>
<td>72</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
After a thorough review of the options trading surrounding Super Micro Computer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Super Micro Computer's Current Market Status</h3>
<ul>
<li>With a volume of 53,554,019, the price of SMCI is down -3.89% at $24.49. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 17 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Super Micro Computer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SMCI

What the Options Market Tells Us About Super Micro Computer

Deep-pocketed investors have adopted a bearish approach towards Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FICO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Fair Isaac. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 42% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $71,378, and 12 are calls, amounting to $737,063.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1700.0 to $2500.0 for Fair Isaac over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Fair Isaac options trades today is 16.6 with a total volume of 51.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Fair Isaac's big money trades within a strike price range of $1700.0 to $2500.0 over the last 30 days.
<h3>Fair Isaac Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731098919_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$352.1</td>
<td>$352.0</td>
<td>$352.1</td>
<td>$2000.00</td>
<td>$352.0K</td>
<td align="right">29</td>
<td align="right">10</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$375.6</td>
<td>$373.0</td>
<td>$375.6</td>
<td>$2000.00</td>
<td>$75.1K</td>
<td align="right">29</td>
<td align="right">12</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$548.0</td>
<td>$538.0</td>
<td>$539.0</td>
<td>$1700.00</td>
<td>$53.9K</td>
<td align="right">4</td>
<td align="right">1</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$55.6</td>
<td>$51.7</td>
<td>$55.6</td>
<td>$2200.00</td>
<td>$44.4K</td>
<td align="right">1</td>
<td align="right">8</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$160.0</td>
<td>$155.1</td>
<td>$160.0</td>
<td>$2180.00</td>
<td>$32.0K</td>
<td align="right">3</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Fair Isaac</h3>
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Having examined the options trading patterns of Fair Isaac, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Fair Isaac Standing Right Now?</h3>
<ul>
<li>With a volume of 196,525, the price of FICO is down 0.0% at $2176.1. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>Expert Opinions on Fair Isaac</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $2252.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Fair Isaac, which currently sits at a price target of $2000. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Sector Perform, setting a price target of $2040. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Fair Isaac, which currently sits at a price target of $2500. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Fair Isaac, which currently sits at a price target of $2374. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Fair Isaac, which currently sits at a price target of $2350. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Fair Isaac with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

FICO

Looking At Fair Isaac's Recent Unusual Options Activity

SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) reported worse-than-expected third-quarter results on Wednesday and analysts are weighing in on what is <a href="https://www.benzinga.com/news/earnings/24/11/41806208/solaredges-tough-q3-revenue-miss-multi-billion-impairment-bleak-forecast-more">next for the company. </a>
Truist on SEDG: Truist analyst Jordan Levy highlighted prior commentary from Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) on weakness in the European market as forewarning for SolarEdge's disappointing results and guidance. 
SolarEdge expects revenue of between $180 million and $200 million for the fourth quarter, below the consensus of $308.66 million. 
Levy said market weakness is cyclical and sees SolarEdge as a "show-me story" over the coming quarters.&nbsp;
Truist reiterated its Hold rating on SolarEdge and lowered its price target from $20 to $15.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
BMO on SEDG: BMO Capital Markets analyst Ameet Thakkar pointed to Solar Edge's "disappointing update" and "meaningfully" lowered the price target on the stock from $21 to $12 as the European market "has gone from bad to worse."&nbsp;
The BMO analyst maintained a Market Perform rating and said SolarEdge should see growth alongside solar demand.&nbsp;
However, Thakkar said the company's management leaves him cautious and he would like to see "more urgency" in the rate of change to the company's cost structure and operational expenditures.&nbsp;
"At this point, given the already over 80% ytd decline in company share price, high short interest, and SEDG belatedly taking more decisive actions to clear its product channel in Europe we await to see if any progress emerges," the BMO analyst wrote.
SEDG Price Action: According to data from Benzinga Pro, SolarEdge Technologies shares are down 9.74% at $13.43 at the time of publication Friday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

ENPH

SEDG

SolarEdge Is A 'Show-Me Story' After Disappointing Q3: Analyst

Peak Bio (PKBO) has released an update to notify the public and investors about the unregistered sales of equity securities. Peak Bio, Inc. has eng...

Peak Bio Raises Capital via Convertible Promissory Notes

Peak Bio (PKBO) has released an update. Peak Bio, Inc. has successfully secured multiple rounds of financing through convertible note agreements wi...

Peak Bio Raises Over $2M Through Convertible Notes

Akari Therapeutics rises on all stock deal with Peak Bio

Akari Therapeutics rises on all-stock merger deal with Peak Bio

The latest update is out from Peak Bio (PKBO). Peak Bio, Inc. has entered into a pivotal Merger Agreement with Akari Therapeutics, leading to Peak ...

Peak Bio's Strategic Merger with Akari Therapeutics

Peak Bio (PKBO) has issued an announcement. David Rosenberg, Michael Friedman, and Stephen LaMond have abruptly resigned from their positions on th...

Peak Bio Board Reshuffle as Three Members Resign

An update from Peak Bio (PKBO) is now available. Peak Bio, Inc. has appointed Sandip Patel as a director and chair of the Audit Committee. With no ...

Peak Bio Appoints Sandip Patel as Director and Audit Chair

An update from Peak Bio (PKBO) is now available. Stephen LaMond has stepped down as the Interim CEO and COO of Peak Bio, Inc., and will transition ...

Peak Bio Announces CEO Transition and New Leadership

Peak Bio ( ($PKBO) ) has provided an update. Peak Bio, Inc. has awarded 4.15 million stock options to its key personnel, including top executives a...

Peak Bio Incentivizes Leadership with Stock Options for Growth

AKTX

PKBO

Press Releases

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Comments

Peak Bio

Notizie

Ultime notizie per Peak Bio (OTC:PKBO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO